SOAT1 and rheumatoid arthritis: Given our results, and the ability of rheumatoid arthritis patients to tolerate low-dose methotrexate over many years, we suggest that methotrexate may ‘dampen’ the pathological over-activation of the JAK/STAT pathway sufficiently to control disease without preventing physiological activation when needed for haematopoiesis or infection response.